Admission to Trading

Summary by AI BETAClose X

Santander UK plc announced on 30 June 2026 the admission to trading on the London Stock Exchange of £2,333,099.00 Equity Index Linked Notes due 2031. These notes were issued under the company's Notes and Certificates programme, referencing a Base Prospectus dated 30 September 2025, supplemented by several updates and specific Final Terms dated 16 March 2026. Full details are available via the London Stock Exchange website.

Disclaimer*

Santander UK Plc
30 June 2026
 

 

SANTANDER UK PLC

(LEI: PTCQB104N23FMNK2RZ28)

NOTES AND CERTIFICATES PROGRAMME

 

NOTIFICATION OF ADMISSION TO TRADING OF TRANSFERABLE SECURITIES

 

The following transferrable securities issued by Santander UK plc (the Issuer) have today 30 June 2026 been admitted to trading on the main market of the London Stock Exchange plc:

 

(1)  Issue of £2,333,099.00 Equity Index Linked Notes due 2031 (the Notes) (XS3305177860).

 

The Notes are issued under the Issuer's Notes and Certificates programme pursuant to a Base Prospectus dated 30 September 2025 (the Base Prospectus) and supplemental prospectuses dated 4 February 2026, 10 March 2026, 1 May 2026 and 5 June, 2026 (the Supplements), read together with the Final Terms dated 16 March 2026.

 

Full information on the Issuer and the offer of the Notes is only available on the basis of the Base Prospectus as supplemented by the Supplements, read together with the applicable Final Terms.

 

The Base Prospectus, the Supplements and the Final Terms have been published on the website of the London Stock Exchange.

 

 

For further information, please contact:

 

Structured Notes Desk

Tel: +44 (0) 20 7756 7000 or structurednotes@santandergbm.com.

 

Please note that the information contained in the Base Prospectus, the Supplement and the Final Terms may be addressed to and/or targeted at persons who are residents of particular countries (specified in the Base Prospectus, the Supplement and/or the Final Terms) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the Base Prospectus, the Supplement and/or the Final Terms is not addressed. Prior to relying on the information contained in the Base Prospectus, the Supplement and/or the Final Terms, you must ascertain from the Base Prospectus, the Supplement and/or the Final Terms whether or not you are part of the intended addressees of the information contained therein.

Your right to access this service is conditional upon complying with the above requirement.

The Final Terms referenced herein does not constitute an offer of securities for sale in the United States. The securities described herein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or under any relevant securities laws of any state of the United States of America, and may not be offered or sold to U.S. persons or to persons within the United States of America, except pursuant to an exemption from the Securities Act.

END

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings